DIAGNOSIS, TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH THE NEUROTENSIN RECEPTOR Russian patent published in 2023 - IPC C07D403/14 C07F5/00 A61K31/395 A61K51/04 A61P35/00 A61P43/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention describes the compound of formula (I).

The invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt thereof

where R¹ is selected from -(C_1-6 alkyl), R² is selected from -(C_1-6 alkyl), R³ is selected from 2-amino-2-adamantanecarboxylic acid, and Z is -(linker group)-( chelator group), where the linker group is -C_1-6 alkylene-N(R⁴)-C_1-6 alkylene-N(R⁴)-, where each R⁴ is independently selected from hydrogen and C_1-6 alkyl, and each C_1-6 alkylene is independently optionally substituted with one substituent selected from OH, where the chelator group is selected from 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 6-hydrazinonicotinic acid (HYNIC) and 2-amino-3-(1-(2-carboxyethyl)-1H-1,2,3-triazol-4-yl)propanoic acid, as well as a compound complex with one or more diagnostically or therapeutically effective radionuclides selected from Cu-62, Cu-64, Cu-67, Tc-99m, Lu-177 and Ac-225, as well as pharmaceutical compositions based on it for the diagnosis and/or treatment of a disorder involving the neurotensin 1 receptor.

EFFECT: obtaining new compounds and complexes that can be used for the diagnosis and/or treatment of a disorder involving the neurotensin 1 receptor.

11 cl, 2 tbl, 3 dwg